LON:SCLP - Scancell Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: GBX 0
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
GBX 22.78
▲ +0.025 (0.11%)
1 month | 3 months | 12 months
Get New Scancell Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SCLP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SCLP

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
GBX 0
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Scancell in the last 3 months. The average price target is GBX 0, with a high forecast of GBX 0 and a low forecast of £100,000. The average price target represents a -100.00% upside from the last price of GBX 22.78.
N/A
The current consensus among 0 polled investment analysts is to n/a stock in Scancell. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/29/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/27/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/26/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/25/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/23/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/21/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/22/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/21/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetDetails
7/11/2017Panmure GordonReiterated RatingBuyGBX 68
i
4/20/2017Panmure GordonReiterated RatingBuyGBX 68
i
2/1/2017Panmure GordonReiterated RatingBuyGBX 68
i
1/26/2017Panmure GordonReiterated RatingBuyGBX 68
i
1/3/2017Panmure GordonReiterated RatingBuyGBX 68
i
10/10/2016Panmure GordonReiterated RatingBuyGBX 68
i
9/16/2016Panmure GordonReiterated RatingBuyGBX 68
i
7/20/2016Panmure GordonReiterated RatingBuyGBX 68
i
7/6/2016Panmure GordonReiterated RatingBuyGBX 68
i
6/17/2016Panmure GordonReiterated RatingBuy
i
(Data available from 4/21/2016 forward)
Scancell logo
Scancell Holdings plc engages in the discovery and development of novel vaccines for the treatment of various cancers. The company's product candidates include SCIB1, which is in phase II clinical trial for the treatment of metastatic melanoma; SCIB2 that is in phase I/II combination trials for the treatment of non-small cell lung cancer; and Modi-1, which is in phase I/II clinical trials for the treatment of head and neck, triple negative breast, ovarian, and renal cancers. It also develops Modi-2 that is in pre-clinical trial for the treatment of multiple solid tumors. The company has a research collaboration agreement with BioNTech to develop T-cell receptor based therapeutics; licensing and collaboration agreement with ISA Pharmaceuticals B.V. to use ISA's AMPLIVANT adjuvant technology for the development and commercialization of Modi-1; and collaboration agreements with Cobra Biologics, Centre for Research on Global Virus Infections, the University of Nottingham, and the Nottingham Trent University to develop a vaccine for COVID-19. Scancell Holdings plc was founded in 1997 and is based in Oxford, the United Kingdom.
Read More

Today's Range

Now: GBX 22.78
22.43
23

50 Day Range

MA: GBX 22.97
21
24.50

52 Week Range

Now: GBX 22.78
4.70
29

Volume

515,012 shs

Average Volume

2,510,691 shs

Market Capitalization

£185.67 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Scancell?

The following equities research analysts have issued stock ratings on Scancell in the last twelve months:
View the latest analyst ratings for SCLP.

What is the current price target for Scancell?

0 Wall Street analysts have set twelve-month price targets for Scancell in the last year. has the lowest price target set, forecasting a price of £100,000 for Scancell in the next year.
View the latest price targets for SCLP.

What is the current consensus analyst rating for Scancell?

Scancell currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for SCLP.

What other companies compete with Scancell?

How do I contact Scancell's investor relations team?

Scancell's physical mailing address is Department of Clinical Oncology Hucknall Road, NOTTINGHAM, NG5 1PB, United Kingdom. The company's listed phone number is +44-115-8231863. The official website for Scancell is www.scancell.co.uk.